Ken Griffin’s Arcturus Therapeutics ARCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $269K | Buy |
+34,782
| New | +$254K | ﹤0.01% | 10725 |
|
|
2025
Q4 | – | Sell |
-42,120
| Closed | -$455K | – | 12600 |
|
|
2025
Q3 | $776K | Buy |
42,120
+13,440
| +47% | +$216K | ﹤0.01% | 8096 |
|
|
2025
Q2 | $373K | Buy |
28,680
+22,337
| +352% | +$264K | ﹤0.01% | 9312 |
|
|
2025
Q1 | $67.2K | Sell |
6,343
-7,334
| -54% | -$116K | ﹤0.01% | 11974 |
|
|
2024
Q4 | $232K | Sell |
13,677
-62,177
| -82% | -$1.17M | ﹤0.01% | 10170 |
|
|
2024
Q3 | $1.76M | Buy |
75,854
+54,222
| +251% | +$1.16M | ﹤0.01% | 5777 |
|
|
2024
Q2 | $527K | Sell |
21,632
-145,462
| -87% | -$4.41M | ﹤0.01% | 7941 |
|
|
2024
Q1 | $5.64M | Buy |
167,094
+166,727
| +45,430% | +$5.91M | ﹤0.01% | 3759 |
|
|
2023
Q4 | $11.6K | Sell |
367
-147,506
| -100% | -$3.51M | ﹤0.01% | 13039 |
|
|
2023
Q3 | $3.78M | Buy |
147,873
+25,962
| +21% | +$800K | ﹤0.01% | 4101 |
|
|
2023
Q2 | $3.5M | Sell |
121,911
-192,878
| -61% | -$5.25M | ﹤0.01% | 4195 |
|
|
2023
Q1 | $7.55M | Buy |
314,789
+11,483
| +4% | +$206K | ﹤0.01% | 3177 |
|
|
2022
Q4 | $5.14M | Buy |
303,306
+112,903
| +59% | +$1.97M | ﹤0.01% | 3818 |
|
|
2022
Q3 | $2.82M | Buy |
190,403
+126,867
| +200% | +$2.13M | ﹤0.01% | 4920 |
|
|
2022
Q2 | $1M | Sell |
63,536
-34,097
| -35% | -$669K | ﹤0.01% | 7009 |
|
|
2022
Q1 | $2.63M | Buy |
97,633
+82,316
| +537% | +$2.1M | ﹤0.01% | 5469 |
|
|
2021
Q4 | $567K | Sell |
15,317
-56,420
| -79% | -$2.3M | ﹤0.01% | 9383 |
|
|
2021
Q3 | $3.43M | Buy |
+71,737
| New | +$3.21M | ﹤0.01% | 5076 |
|
|
2021
Q2 | – | Sell |
-190,621
| Closed | -$6.45M | – | 13616 |
|
|
2021
Q1 | $7.87M | Buy |
190,621
+152,371
| +398% | +$9.08M | ﹤0.01% | 3362 |
|
|
2020
Q4 | $1.66M | Sell |
38,250
-271,999
| -88% | -$18.4M | ﹤0.01% | 5768 |
|
|
2020
Q3 | $13.3M | Sell |
310,249
-388,035
| -56% | -$19.3M | ﹤0.01% | 1966 |
|
|
2020
Q2 | $32.6M | Buy |
698,284
+683,546
| +4,638% | +$23.6M | 0.01% | 1096 |
|
|
2020
Q1 | $200K | Buy |
14,738
+1,805
| +14% | +$23.1K | ﹤0.01% | 8013 |
|
|
2019
Q4 | $141K | Buy |
+12,933
| New | +$135K | ﹤0.01% | 8392 |
|
|
2017
Q2 | – | Sell |
-14,302
| Closed | -$114K | – | 7439 |
|
|
2017
Q1 | $114K | Buy |
+14,302
| New | +$132K | ﹤0.01% | 6808 |
|
|
2016
Q4 | – | Sell |
-2,085
| Closed | -$31.2K | – | 7216 |
|
|
2016
Q3 | $36K | Buy |
+2,085
| New | +$67.3K | ﹤0.01% | 6922 |
|
|
2016
Q1 | – | Sell |
-676
| Closed | -$22.9K | – | 6713 |
|
|
2015
Q4 | $30K | Buy |
+676
| New | +$30.4K | ﹤0.01% | 7667 |
|
|
2015
Q3 | – | Sell |
-149
| Closed | -$7K | – | 8853 |
|
|
2015
Q2 | $7K | Sell |
149
-1,946
| -93% | -$89.2K | ﹤0.01% | 8471 |
|
|
2015
Q1 | $83K | Buy |
2,095
+1,244
| +146% | +$54.7K | ﹤0.01% | 6993 |
|
|
2014
Q4 | $22K | Buy |
+851
| New | +$27.1K | ﹤0.01% | 7729 |
|
Other funds holding ARCT
AIM
NAMA
VCM
VPM
Ken Griffin's ARCT Position: Q1 2026 in Review
Ken Griffin opened a new position in Arcturus Therapeutics (ARCT) in Q1 2026: 34,782 shares worth $269K. The stake represents ﹤0.01% of the portfolio and ranks #10725 among its holdings. This is a return to the name: Ken Griffin previously reported a position in ARCT as recently as Q3 2025.
Ken Griffin first reported a position in ARCT in Q4 2014 and has held it in 30 quarters since. The position peaked at $32.6M in Q2 2020. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.
- Ken Griffin held 34,782 shares of Arcturus Therapeutics worth $269K as of Q1 2026.
- Arcturus Therapeutics was a new Ken Griffin position in Q1 2026.
- Arcturus Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #10725 holding.
- Ken Griffin first reported a position in Arcturus Therapeutics in Q4 2014 and has held it in 30 quarters since.
- Ken Griffin's Arcturus Therapeutics position peaked at $32.6M in Q2 2020.
- 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.